JP2017532961A5 - - Google Patents

Download PDF

Info

Publication number
JP2017532961A5
JP2017532961A5 JP2017520449A JP2017520449A JP2017532961A5 JP 2017532961 A5 JP2017532961 A5 JP 2017532961A5 JP 2017520449 A JP2017520449 A JP 2017520449A JP 2017520449 A JP2017520449 A JP 2017520449A JP 2017532961 A5 JP2017532961 A5 JP 2017532961A5
Authority
JP
Japan
Prior art keywords
smad7
composition
antisense oligonucleotide
item
ibd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017520449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017532961A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/074066 external-priority patent/WO2016059239A1/en
Publication of JP2017532961A publication Critical patent/JP2017532961A/ja
Publication of JP2017532961A5 publication Critical patent/JP2017532961A5/ja
Pending legal-status Critical Current

Links

JP2017520449A 2014-10-17 2015-10-16 Smad7アンチセンスオリゴヌクレオチドによる対象を処置するための方法および組成物 Pending JP2017532961A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462065598P 2014-10-17 2014-10-17
US62/065,598 2014-10-17
PCT/EP2015/074066 WO2016059239A1 (en) 2014-10-17 2015-10-16 Methods and compositions for treating a subject with a smad7 antisense oligonucleotide

Publications (2)

Publication Number Publication Date
JP2017532961A JP2017532961A (ja) 2017-11-09
JP2017532961A5 true JP2017532961A5 (enExample) 2018-11-29

Family

ID=54330761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017520449A Pending JP2017532961A (ja) 2014-10-17 2015-10-16 Smad7アンチセンスオリゴヌクレオチドによる対象を処置するための方法および組成物

Country Status (12)

Country Link
US (2) US10337004B2 (enExample)
EP (1) EP3207136A1 (enExample)
JP (1) JP2017532961A (enExample)
KR (1) KR20170069262A (enExample)
CN (1) CN107406851A (enExample)
AU (1) AU2015332624A1 (enExample)
CA (1) CA2964667A1 (enExample)
EA (1) EA201790867A1 (enExample)
IL (1) IL251717A0 (enExample)
MA (1) MA43331A (enExample)
MX (1) MX2017004973A (enExample)
WO (1) WO2016059239A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
JP5719776B2 (ja) 2008-11-13 2015-05-20 ノグラ ファーマ リミテッド アンチセンス組成物およびその作製および使用
WO2013037970A1 (en) 2011-09-15 2013-03-21 Nogra Pharma Limited Methods for monitoring responsiveness to anti-smad7 therapy
NZ630914A (en) 2012-04-18 2017-01-27 Nogra Pharma Ltd Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
KR20170005058A (ko) 2014-05-09 2017-01-11 노그라 파마 리미티드 염증성 장 질환을 치료하는 방법
US20170233736A1 (en) * 2014-10-17 2017-08-17 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
US10337004B2 (en) 2014-10-17 2019-07-02 Nogra Pharma Limited Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
JP2019505598A (ja) * 2016-02-23 2019-02-28 セルジーン アルパイン インベストメント カンパニー Ii, エルエルシー Smad7の阻害を用いて、腸線維症を治療する方法
WO2018122376A1 (en) * 2016-12-30 2018-07-05 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis
EP4139459A2 (en) * 2020-04-24 2023-03-01 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotides (aso) and methods of using the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1456380B1 (en) 2001-11-02 2012-04-18 Giuliani International Limited Smad7 inhibitors for the treatment of cns diseases
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
JP5719776B2 (ja) 2008-11-13 2015-05-20 ノグラ ファーマ リミテッド アンチセンス組成物およびその作製および使用
CA2750584A1 (en) * 2009-01-26 2010-07-29 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Means and methods for modulating notch3 protein expression and/or the coding region of notch3; compositions and use thereof in the treatment of cadasil
US9006198B2 (en) * 2010-02-08 2015-04-14 Isis Pharmaceuticals, Inc. Selective reduction of allelic variants
WO2013037970A1 (en) * 2011-09-15 2013-03-21 Nogra Pharma Limited Methods for monitoring responsiveness to anti-smad7 therapy
NZ630914A (en) 2012-04-18 2017-01-27 Nogra Pharma Ltd Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
JP6502863B2 (ja) 2013-03-15 2019-04-17 ノグラ ファーマ リミテッド 結腸直腸癌を処置する方法
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
KR20170005058A (ko) 2014-05-09 2017-01-11 노그라 파마 리미티드 염증성 장 질환을 치료하는 방법
JP2017532982A (ja) 2014-10-17 2017-11-09 セルジーン アルパイン インベストメント カンパニー Ii, エルエルシー Smad7アンチセンスオリゴヌクレオチドの同位体置換体
US10337004B2 (en) 2014-10-17 2019-07-02 Nogra Pharma Limited Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
US20170233736A1 (en) 2014-10-17 2017-08-17 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
MA41271A (fr) 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
EP3356530A4 (en) 2015-09-30 2019-04-10 Celgene Alpine Investment Company II, LLC TLR-MODULATORS AND METHOD OF USE
EP3355896A2 (en) 2015-09-30 2018-08-08 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression

Similar Documents

Publication Publication Date Title
JP2017532961A5 (enExample)
Silva et al. Long noncoding RNAs: a missing link in osteoporosis
US10767178B2 (en) Compositions and methods of using piRNAS in cancer diagnostics and therapeutics
Usman et al. Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics
Jenner et al. Insights into host responses against pathogens from transcriptional profiling
CN101892311B (zh) 高血压易感基因的单核苷酸多态性位点rs7550536的检测方法及检测试剂盒
CN102586408B (zh) 高血压易感基因Mfn2单核苷酸多态性位点rs3820189的检测方法及检测试剂盒
CN101892305B (zh) 高血压易感基因的rs2295281位点的检测方法及检测试剂盒
CN109414448A (zh) 用于减少PAPD5或PAPD7 mRNA治疗乙型肝炎感染的核酸分子
US10337004B2 (en) Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
JP2017505623A5 (enExample)
JP2018517704A5 (enExample)
FI3384049T3 (fi) Menetelmiä geenimuunnosten liittämiseksi kliiniseen tulokseen potilailla, jotka kärsivät silmänpohjan ikärappeumasta ja joita on hoidettu anti-VEGF:llä
JP6612232B2 (ja) 対象のマルチキナーゼ阻害剤に対する応答性を予測する遺伝子発現シグネチャ、及びその使用
US20180263979A1 (en) Combination of raf inhibitors and aurora kinase inhibitors
JPWO2011027893A1 (ja) 慢性c型肝炎の治療効果予測方法
CN101892297B (zh) 高血压易感基因单核苷酸多态性位点的检测方法及其试剂盒
Yang et al. Fibronectin is essential for hepatitis B virus propagation in vitro: may be a potential cellular target?
Day et al. Unsaturated fatty acid regulation of AraC/XylS transcription factors
JP2011193786A (ja) C型肝炎の治療効果を予測するためのマーカー群、検査方法及び検査用キット
CN105497900A (zh) 一种抗未分化甲状腺癌耐药靶点及其应用
CN110438262B (zh) 一种乙型肝炎病毒分型和耐药基因检测试剂盒
JP7498448B2 (ja) SNHG12遺伝子に由来するncRNAの発現抑制剤を有効成分とするがん増殖抑制剤
CN118265529A (zh) 使用camp应答元件结合蛋白3样3(creb3l3)抑制剂的肝病治疗
WO2025049568A1 (en) Treatment of muscle disorder with folliculin interacting protein 1 (fnip1) inhibitors and/or folliculin (flcn) inhibitors